Restore Vision has conducted the first comprehensive review of FDA-approved excipients in ophthalmic medications, examining their roles, safety, and the regulatory pathways required for approval for human use.
restorevision@catalyze-group.com
Restore Vision’s first review meeting
On January, 16 the RESTORE VISION team held its first review meeting to assess project progress and discuss plans for the upcoming year.
Partecipa al nostro studio presso l’Ospedale San Raffaele di Milano!
Aiutaci a far progredire la ricerca sulle malattie oculari rare!
Participate in our study in Milan, Italy!
Join our study in Milan, Italy and help us advance research on rare eye conditions!
Restore Vision at EVER 2024
Read more about Restore Vision Special Interest Session at EVER 2024 Congress
Restore Vision team participates in DOG 2024 Congress
Last October 10, the Restore Vision team participated in the Deutsche Ophthalmologische Gesellschaft – DOG 2024.
Restore Vision 2nd consortium meeting
One year after the project kicked-off, our team met again in-person in Stockholm!
Restore Vision partners jointly host the 7th European Anirida Conference
Restore Vision partners participated in 7th European Aniridia Conference.
Antisense eye drops only or combined with fine needle diathermy could be used to regress corneal neovascularization in mice – study by UKK
At the recent ARVO meeting, Wei Zhang presented the latest findings from the University of Cologne on a new treatment to regress corneal neovascularization in mice
Genetic research shows promise for developing a treatment for the rare eye disease Aniridia – Study by UKK
At the recent ARVO meeting, Karina Hadriaan presented the latest findings from the University of Cologne on a new treatment to regress corneal neovascularization in mice